2024 |
Santhanes D, Zhang H, Wilkins A, Aitken RJ, Gannon A-L, Liang M, 'Precise control of microfluidic flow conditions is critical for harnessing the in vitro transfection capability of pDNA-loaded lipid-Eudragit nanoparticles.', Drug Deliv Transl Res, (2024) [C1]
|
|
|
2024 |
Fraser B, Wilkins A, Whiting S, Liang M, Rebourcet D, Nixon B, Aitken RJ, 'Development of peptides for targeting cell ablation agents concurrently to the Sertoli and Leydig cell populations of the testes: An approach to non-surgical sterilization.', PLoS One, 19 e0292198 (2024) [C1]
|
|
Nova |
2023 |
Baldelli A, Liang M, 'Design of respirable sprayed microparticles of encapsulated bacteriophages', Frontiers in Drug Delivery, 3 [C1]
|
|
Nova |
2023 |
Mohanan S, Sathish CI, Ramadass K, Liang M, Vinu A, 'Design and Synthesis of Cabazitaxel Loaded Core-Shell Mesoporous Silica Nanoparticles with Different Morphologies for Prostate Cancer Therapy', Small, [C1]
|
|
|
2023 |
Al-Theyab NS, Abuelizz HA, Al-Hamoud GA, Aldossary A, Liang M, 'Priestia megaterium Metabolism: Isolation, Identification of Naringenin Analogues and Genes Elevated Associated with Nanoparticle Intervention', Current Issues in Molecular Biology, 45 6704-6716 [C1]
|
|
Nova |
2023 |
Al-Theyab N, Alrasheed O, Abuelizz HA, Liang M, 'Draft genome sequence of potato crop bacterial isolates and nanoparticles-intervention for the induction of secondary metabolites biosynthesis', Saudi Pharmaceutical Journal, 31 783-794 (2023) [C1]
|
|
Nova |
2023 |
Mohanan S, Guan X, Liang M, Karakoti A, Vinu A, 'Stimuli-Responsive Silica Silanol Conjugates: Strategic Nanoarchitectonics in Targeted Drug Delivery.', Small, e2301113 (2023) [C1]
|
|
|
2023 |
Mohanan S, Sathish CI, Adams TJ, Kan S, Liang M, Vinu A, 'A Dual Protective Drug Delivery System Based on Lipid Coated Core-Shell Mesoporous Silica for Efficient Delivery of Cabazitaxel to Prostate Cancer Cells', Bulletin of the Chemical Society of Japan, 96 1188-1195 (2023) [C1]
|
|
Nova |
2022 |
Gao H, Kan S, Ye Z, Feng Y, Jin L, Zhang X, et al., 'Development of in silico methodology for siRNA lipid nanoparticle formulations', Chemical Engineering Journal, 442 (2022) [C1]
|
|
Nova |
2022 |
Santhanes D, Wilkins A, Zhang H, John Aitken R, Liang M, 'Microfluidic formulation of lipid/polymer hybrid nanoparticles for plasmid DNA (pDNA) delivery', International Journal of Pharmaceutics, 627 122223-122223 (2022) [C1]
|
|
Nova |
2022 |
Kan S, Grainge C, Nichol K, Reid A, Knight D, Sun Y, et al., 'TLR7 agonist loaded airway epithelial targeting nanoparticles stimulate innate immunity and suppress viral replication in human bronchial epithelial cells', INTERNATIONAL JOURNAL OF PHARMACEUTICS, 617 (2022) [C1]
|
|
Nova |
2021 |
Fraser B, Peters AE, Sutherland JM, Liang M, Rebourcet D, Nixon B, Aitken RJ, 'Biocompatible Nanomaterials as an Emerging Technology in Reproductive Health; a Focus on the Male', Frontiers in Physiology, 12 (2021) [C1]
A growing body of research has confirmed that nanoparticle (NP) systems can enhance delivery of therapeutic and imaging agents as well as prevent potentially damaging systemic exp... [more]
A growing body of research has confirmed that nanoparticle (NP) systems can enhance delivery of therapeutic and imaging agents as well as prevent potentially damaging systemic exposure to these agents by modifying the kinetics of their release. With a wide choice of NP materials possessing different properties and surface modification options with unique targeting agents, bespoke nanosystems have been developed for applications varying from cancer therapeutics and genetic modification to cell imaging. Although there remain many challenges for the clinical application of nanoparticles, including toxicity within the reproductive system, some of these may be overcome with the recent development of biodegradable nanoparticles that offer increased biocompatibility. In recognition of this potential, this review seeks to present recent NP research with a focus on the exciting possibilities posed by the application of biocompatible nanomaterials within the fields of male reproductive medicine, health, and research.
|
|
Nova |
2020 |
Chen E, Han S, Song B, Xu L, Yuan H, Liang M, Sun Y, 'Mechanism investigation of hyaluronidase-combined multistage nanoparticles for solid tumor penetration and antitumor effect', International Journal of Nanomedicine, 15 6311-6324 (2020) [C1]
Background: Hyaluronic acid (HA) is a major component of extracellular matrix (ECM) and its over expression in tumor tissues contributes to the increase of interstitial fluid pres... [more]
Background: Hyaluronic acid (HA) is a major component of extracellular matrix (ECM) and its over expression in tumor tissues contributes to the increase of interstitial fluid pressure (IFP) and hinders the penetration of nanoparticles into solid tumors. Materials and Methods: We here reported a tumoral microenvironment responsive multi-stage drug delivery system (NPs-EPI/HAase) which was formed layer by layer via electrostatic interaction with epirubicin (EPI)-loaded PEG-b-poly(2-(diisopropylamino)ethyl methacrylate)-b-poly(2-guanidinoethylmethacrylate) (mPEG-PDPA-PG, PEDG) micelles (NPs-EPI) and hyaluronidase (HAase). In this paper, we focused on the hyaluronidase-combined nanoparticles (NPs-EPI/HAase) for tumor penetration in tumor spheroid and solid tumor models in vitro and in vivo. Results: Our results showed that NPs-EPI/HAase effectively degrade the HA in ECM and facilitate deep penetration of NPs-EPI into solid tumor. Moreover, NPs-EPI mainly employed clathrin-mediated and macropinocytosis-mediated endocytic pathways for cellular uptake and were subsequently directed to the lysosomes for further drug release triggered by proton sponge effect. Compared with NPs-EPI, the HAase coating group showed an enhanced tumoral drug delivery efficacy and inhibition of tumor growth. Conclusion: Overall, our studies demonstrated that coating nanoparticles with HAase can provide a simple but efficient strategy for nano-drug carriers to enhance solid tumor penetration and chemotherapeutic efficacy.
|
|
Nova |
2020 |
Kan S, Hariyadi DM, Grainge C, Knight DA, Bartlett NW, Liang M, 'Airway epithelial-targeted nanoparticles for asthma therapy', AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 318 L500-L509 (2020) [C1]
|
|
Nova |
2019 |
Du C, Liang Y, Ma Q, Sun Q, Qi J, Cao J, et al., 'Intracellular tracking of drug release from pH-sensitive polymeric nanoparticles via FRET for synergistic chemo-photodynamic therapy', JOURNAL OF NANOBIOTECHNOLOGY, 17 (2019) [C1]
|
|
Nova |
2019 |
Ge R, Cao J, Chi J, Han S, Liang Y, Xu L, et al., 'NIR-guided dendritic nanoplatform for improving antitumor efficacy by combining chemo-phototherapy', International Journal of Nanomedicine, Volume 14 4931-4947 (2019) [C1]
|
|
Nova |
2017 |
Shargh VH, Hondermarck H, Liang M, 'Gelatin-albumin hybrid nanoparticles as matrix metalloproteinases-degradable delivery systems for breast cancer therapy', Nanomedicine, 12 977-989 (2017) [C1]
Aim: To develop matrix metalloproteinase-responsive gelatin-albumin hybrid nanoparticles encapsulating a selective tropomyosin receptor kinase A (TrkA) inhibitor GNF-5837 (Gel-Alb... [more]
Aim: To develop matrix metalloproteinase-responsive gelatin-albumin hybrid nanoparticles encapsulating a selective tropomyosin receptor kinase A (TrkA) inhibitor GNF-5837 (Gel-Alb-GNF HNPs) and to demonstrate their anticancer effects in breast cancer. Methods: Gel-Alb-GNF HNPs were prepared using a pH-controlled complexation process from cationic gelatin, dextran sulfate and albumin-bound GNF-5837. The anticancer activities of Gel-Alb-GNF HNPs were tested in a panel of subtype-specific breast cancer cell lines. Results: Gel-Alb-GNF HNPs (~130 nm) displayed excellent stability and matrix metalloproteinase-triggered drug release. Compared with GNF-5837 alone, Gel-Alb-GNF HNPs not only significantly enhanced the antiproliferative and anti-invasive effects but also restored the apoptosis of cancer cells. Conclusion: Gel-Alb-GNF HNPs may be adaptable for stand-alone therapies or used in combination with traditional chemotherapies for breast cancer treatment.
|
|
Nova |
2016 |
Shargh VH, Hondermarck H, Liang M, 'Antibody-targeted biodegradable nanoparticles for cancer therapy', Nanomedicine, 11 63-79 (2016) [C1]
The use of nanotechnology has great potentials to revolutionize the future cancer diagnosis and therapy. In this context, various nanoparticles (NPs) have been developed for targe... [more]
The use of nanotechnology has great potentials to revolutionize the future cancer diagnosis and therapy. In this context, various nanoparticles (NPs) have been developed for targeted delivery of diagnostic/therapeutic agents to the tumor sites, which thus result in greater efficacy and much less side effects. The targeting property of NPs is often achieved by functionalizing their surface with tumor-specific ligands, such as antibodies, peptides, small molecules and oligonucleotides. In this review, we will discuss recent progress in the multifunctional design of antibody-targeted NPs with a special focus on liposomal, polymeric and protein-based delivery systems.
|
|
Nova |
2016 |
Shargh VH, Hondermarck H, Liang M, 'Albumin hybrid nanoparticles loaded with tyrosine kinase A inhibitor GNF-5837 for targeted inhibition of breast cancer cell growth and invasion.', Int J Pharm, 515 527-534 (2016) [C1]
|
|
Nova |
2015 |
Noorani L, Stenzel M, Liang R, Pourgholami MH, Morris DL, 'Albumin nanoparticles increase the anticancer efficacy of albendazole in ovarian cancer xenograft model', Journal of Nanobiotechnology, 13 (2015) [C1]
|
|
Nova |
2014 |
Jiang Y, Liang M, Svejkar D, Hart-Smith G, Lu H, Scarano W, Stenzel MH, 'Albumin-micelles via a one-pot technology platform for the delivery of drugs', Chemical Communications, 50 6394-6394 (2014) [C1]
|
|
Nova |
2014 |
Noorani L, Pourgholami MH, Liang M, Morris DL, Stenzel M, 'Albendazole loaded albumin nanoparticles for ovarian cancer therapy', European Journal of Nanomedicine, 6 227-236 (2014) [C1]
Albendazole (ABZ), a well-established antiparasitic drug, has been shown to suppress tumor growth in a number of preclinical models of cancer. However, the low solubility of ABZ l... [more]
Albendazole (ABZ), a well-established antiparasitic drug, has been shown to suppress tumor growth in a number of preclinical models of cancer. However, the low solubility of ABZ limits its use as a systemic anticancer agent. To enable systemic administration, we have formulated ABZ into albumin nanoparticles with a size range of 200-300 nm, which were cross-linked with glutaraldehyde to stabilize the nanoparticles and to introduce pH-responsive features. Drug release studies demonstrated that about 20% of ABZ was released at neutral pH within a week in comparison to 70% at slightly acidic condition (pH 5). Cellular uptake studies using ovarian cancer cells indicated that nanoparticles were internalized efficiently within 1 h of incubation. Further, cell proliferation results demonstrated that albumin nanoparticles alone showed no cytotoxicity to both normal and cancer cells. In contrast, the drug-loaded nanoparticles exhibited cellular toxicity and high killing efficacy to cancer cells compared to normal cells. Collectively, our results suggest that these albumin nanoparticles may hold great potentials as ABZ carriers for cancer therapy.
|
|
Nova |
2013 |
Deng ZJ, Liang M, Toth I, Monteiro M, Minchin RF, 'Plasma protein binding of positively and negatively charged polymer-coated gold nanoparticles elicits different biological responses', Nanotoxicology, 7 314-322 (2013) [C1]
|
|
|
2012 |
Yhaya F, Sutinah A, Gregory AM, Liang M, Stenzel MH, 'RAFT polymerization of vinyl methacrylate and subsequent conjugation via enzymatic thiol-ene chemistry', Journal of Polymer Science Part A: Polymer Chemistry, 50 4085-4093 (2012) [C1]
|
|
|
2012 |
Lin I-C, Liang M, Liu T-Y, Jia Z, Monteiro M, Toth I, 'Effect of polymer grafting density on silica nanoparticle toxicity', Bioorganic and Medicinal Chemistry, 20 6862-6869 (2012) [C1]
|
|
|
2012 |
Lin I-C, Liang M, Liu T-Y, Monteiro MJ, Toth I, 'Cellular transport pathways of polymer coated gold nanoparticles', Nanomedicine: Nanotechnology Biology and Medicine, 8 8-11 (2012) [C1]
|
|
|
2012 |
Deng ZJ, Liang M, Toth I, Monteiro MJ, Minchin RF, 'Molecular Interaction of Poly(acrylic acid) Gold Nanoparticles with Human Fibrinogen', ACS Nano, 6 8962-8969 (2012) [C1]
|
|
|
2011 |
Lin I-C, Liang M, Liu T-Y, Ziora ZM, Monteiro MJ, Toth I, 'Interaction of Densely Polymer-Coated Gold Nanoparticles with Epithelial Caco-2 Monolayers', Biomacromolecules, 12 1339-1348 (2011) [C1]
|
|
|
2011 |
Deng ZJ, Liang M, Monteiro MJ, Toth I, Minchin RF, 'Nanoparticle-induced unfolding of fibrinogen promotes Mac-1 receptor activation and inflammation', Nature Nanotechnology, 6 39-44 (2011) [C1]
|
|
|
2011 |
Yhaya F, Lim J, Kim Y, Liang M, Gregory AM, Stenzel MH, 'Development of Micellar Novel Drug Carrier Utilizing Temperature-Sensitive Block Copolymers Containing Cyclodextrin Moieties', Macromolecules, 44 8433-8445 (2011) [C1]
|
|
|
2010 |
Liang M, Lin I-C, Whittaker MR, Minchin RF, Monteiro MJ, Toth I, 'Cellular uptake of densely packed polymer coatings on gold nanoparticles', ACS Nano, 4 403-413 (2010) [C1]
|
|
|
2009 |
Wu SY, Putral LN, Liang M, Chang H-I, Davies NM, McMillan NAJ, '. Development of a novel method for formulating stable siRNA-loaded lipid particles for in vivo use', Pharmaceutical Research, 26 512-522 (2009) [C1]
|
|
|
2008 |
Sarpietro MG, Micieli D, Pignatello R, Liang M, Toth I, Castelli F, 'Effect of variation in the chain number and length in modulating the interaction of immunogenic lipopeptide with biomembrane models', Thermochimica Acta, 471 14-19 (2008) [C1]
|
|
|
2008 |
Liang M, Davies NM, Toth I, 'Increasing entrapment of peptides within poly(alkyl cyanoacrylate) nanoparticles prepared by interfacial polymerization of water-in-oil microemulsions', International Journal of Pharmaceutics, 362 141-146 (2008) [C1]
|
|
|
2008 |
Koda Y, Liang M, Blanchfield JT, Toth I, 'In vitro stability and permeability studies of liposomal delivery systems for a novel lipophilic endomorphin 1 analogue', International Journal of Pharmaceutics, 356 37-43 (2008) [C1]
|
|
|
2008 |
Liang M, Davies NM, Toth I, 'A novel method for preparing immune stimulating complexes (ISCOMs) by hydration of freeze-dried lipid matrix', European Journal of Pharmaceutics and Biopharmaceutics, 68 840-845 (2008) [C1]
|
|
|
2006 |
Liang M, Davies NM, Blanchfield JT, Toth I, 'Particulate systems as adjuvants and carriers for peptide and protein antigen', Current Drug Delivery, 3 379-388 (2006) [C1]
|
|
|
2005 |
Liang M, Davies NM, Toth I, 'Encapsulation of lipopeptides within liposomes: Effect of number of lipid chains, chain length and method of liposome preparation', International Journal of Pharmaceutics, 301 247-254 (2005) [C1]
|
|
|
2002 |
Wang DX, Liang MT, Tian GJ, Lin H, Liu HQ, 'A facile pathway to synthesize diketopiperazine derivatives', TETRAHEDRON LETTERS, 43 865-867 (2002)
|
|
|
2002 |
Liang M, Wang DX, 'Concise and efficient synthesis of dehydropeptide analogues from unsaturated 5(4H)-oxazolone', CHINESE CHEMICAL LETTERS, 13 199-200 (2002)
|
|
|
2002 |
Liang M, Wang DX, 'Synthesis of 2-amino-3-arylnorbornane-2-carboxylic acid analogues', Chinese Journal of Medicinal Chemistry, 27-30 (2002) |
|
|
2001 |
Liang M, Wang DX, 'Progress in the synthesis and application of beta-lactam', CHINESE JOURNAL OF ORGANIC CHEMISTRY, 97-101 (2001)
|
|
|